down arrow

Marksans Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE750C01026
  • NSEID: MARKSANS
  • BSEID: 524404
INR
204.05
9.55 (4.91%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 14.67 lacs

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

202.40211.00

52 Week

130.15358.50
Valuation
Technical
Day's Volume

CASH

14.67 lacs (-29.29%) Volume

Shareholding (Dec 2024)

FII

21.96%

Held by 130 FIIs

DII

4.30%

Held by 15 DIIs

Promoter

43.87%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate 5.08% of over the last 5 years

 
2

Stock is technically in a Bearish range

3

With ROE of 15.2, it has a Expensive valuation with a 3.9 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 9,247 Cr (Mid Cap)

stock-summary
P/E

24.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.31%

stock-summary
Debt Equity

-0.21

stock-summary
Return on Equity

15.21%

stock-summary
Price to Book

3.86

Revenue and Profits (1 Year):
Net Sales:
682 Cr
(Quarterly Results - Dec 2024)
Net Profit:
105 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.31%)
TimePeriod
Price Return
Dividend Return
Total Return
6 Months
-29.59%
0%
-29.59%
1 Year
24.38%
0.36%
24.74%
2 Years
182.85%
1.43%
184.28%
3 Years
245.85%
2.97%
248.82%
4 Years
265.03%
2.22%
267.25%
5 Years
849.51%
8.65%
858.16%

Latest dividend: 0.6 per share ex-dividend date: Sep-17-2024

Risk Adjusted Returns v/s Sensex stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
19.01%
EBIT Growth (5y)
5.08%
EBIT to Interest (avg)
35.46
Debt to EBITDA (avg)
0.26
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.27
Tax Ratio
24.30%
Dividend Payout Ratio
8.67%
Pledged Shares
0
Institutional Holding
26.26%
ROCE (avg)
35.84%
ROE (avg)
18.70%
Valuation key factors
Factor
Value
P/E Ratio
24
Industry P/E
33
Price to Book Value
3.86
EV to EBIT
19.36
EV to EBITDA
16.27
EV to Capital Employed
4.61
EV to Sales
3.37
PEG Ratio
1.49
Dividend Yield
0.31%
ROCE (Latest)
23.44%
ROE (Latest)
15.21%
Tecnicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 9 Schemes (3.15%)

FIIs

Held by 130 FIIs (21.96%)

Promoter with highest holding

Mark Saldanha (43.8%)

Highest Public shareholder

Orbimed Asia Iv Mauritius Fvci Limited (10.88%)

Individual Investors Holdings

26.24%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 6.22% vs 8.69% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 8.11% vs 8.98% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "681.85",
          "val2": "641.92",
          "chgp": "6.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "138.77",
          "val2": "135.68",
          "chgp": "2.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.67",
          "val2": "2.63",
          "chgp": "1.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "104.56",
          "val2": "96.72",
          "chgp": "8.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.35%",
          "val2": "21.14%",
          "chgp": "-0.79%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2024 is 19.52% vs 16.35% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2024 is 21.88% vs 25.80% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,232.54",
          "val2": "1,031.27",
          "chgp": "19.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "264.11",
          "val2": "215.91",
          "chgp": "22.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.56",
          "val2": "3.20",
          "chgp": "73.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "185.47",
          "val2": "152.18",
          "chgp": "21.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.43%",
          "val2": "20.94%",
          "chgp": "0.49%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 18.36% vs 18.39% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 23.20% vs 27.68% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,914.39",
          "val2": "1,617.40",
          "chgp": "18.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "402.88",
          "val2": "348.93",
          "chgp": "15.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.23",
          "val2": "6.36",
          "chgp": "29.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "290.03",
          "val2": "235.42",
          "chgp": "23.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.04%",
          "val2": "21.57%",
          "chgp": "-0.53%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2024 is 17.56% vs 24.23% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2024 is 17.80% vs 44.29% in Mar 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,177.41",
          "val2": "1,852.14",
          "chgp": "17.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "458.58",
          "val2": "339.32",
          "chgp": "35.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "11.20",
          "val2": "9.13",
          "chgp": "22.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "313.70",
          "val2": "266.31",
          "chgp": "17.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.06%",
          "val2": "18.32%",
          "chgp": "2.74%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQstock-summary
Dec'24
Sep'24
Change(%)
Net Sales
681.85
641.92
6.22%
Operating Profit (PBDIT) excl Other Income
138.77
135.68
2.28%
Interest
2.67
2.63
1.52%
Exceptional Items
0.00
0.00
Consolidate Net Profit
104.56
96.72
8.11%
Operating Profit Margin (Excl OI)
20.35%
21.14%
-0.79%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2024 is 6.22% vs 8.69% in Sep 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is 8.11% vs 8.98% in Sep 2024

All Quarterly Resultsstock-summary
Half Yearly Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
1,232.54
1,031.27
19.52%
Operating Profit (PBDIT) excl Other Income
264.11
215.91
22.32%
Interest
5.56
3.20
73.75%
Exceptional Items
0.00
0.00
Consolidate Net Profit
185.47
152.18
21.88%
Operating Profit Margin (Excl OI)
21.43%
20.94%
0.49%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2024 is 19.52% vs 16.35% in Sep 2023

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2024 is 21.88% vs 25.80% in Sep 2023

All Half Yearly Resultsstock-summary
Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,914.39
1,617.40
18.36%
Operating Profit (PBDIT) excl Other Income
402.88
348.93
15.46%
Interest
8.23
6.36
29.40%
Exceptional Items
0.00
0.00
Consolidate Net Profit
290.03
235.42
23.20%
Operating Profit Margin (Excl OI)
21.04%
21.57%
-0.53%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 18.36% vs 18.39% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is 23.20% vs 27.68% in Dec 2023

All Nine Monthly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'24stock-summary
Mar'24
Mar'23
Change(%)
Net Sales
2,177.41
1,852.14
17.56%
Operating Profit (PBDIT) excl Other Income
458.58
339.32
35.15%
Interest
11.20
9.13
22.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
313.70
266.31
17.80%
Operating Profit Margin (Excl OI)
21.06%
18.32%
2.74%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2024 is 17.56% vs 24.23% in Mar 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2024 is 17.80% vs 44.29% in Mar 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Marksans Pharma Ltd stock-summary
stock-summary
Marksans Pharma Ltd
Mid Cap
Pharmaceuticals & Drugs
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.
Company Coordinates stock-summary
Company Details
11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W) Mumbai Maharashtra : 400053
stock-summary
Tel: 91-22-40012000
stock-summary
http://www.marksanspharma.com
stock-summary
companysecretary@marksanspharma.com
Registrar Details
Bigshare Services Pvt Ltd , E-2 , Ansa Industrial Estate, Saki Vihar Road, Saki Naka, Andheri (E), Mumbai
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."